Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic<i>ANK3-RET</i>Fusion in<i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer
Edyta Maria Urbanska, Jens Benn Sørensen, Linea Cecilie Melchior, Junia C. Costa, Eric Santoni‐Rugiu
Topics & Concepts
OsimertinibMedicineLung cancerCancer researchOncologyInternal medicineCancerEpidermal growth factor receptorErlotinibLung Cancer Treatments and MutationsLung Cancer Research StudiesGastric Cancer Management and Outcomes